Skip to main
  1. Stocks
  2. Tango Therapeutics
  3. Forecast
TNGX

Tango Therapeutics (TNGX) Stock Forecast & Price Target

Tango Therapeutics (TNGX) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 40%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Tango Therapeutics is supported by a compelling clinical thesis centered on vopimetostat, whose PRMT5-based combinations produced strong updated efficacy in 2L+ PDAC, including an 82% ORR, 100% DCR, and 88% 9-month PFS rate, with similarly encouraging activity in NSCLC. The company’s balance sheet also strengthens the outlook, as it ended 3Q26 with $977.5M in cash, cash equivalents, and marketable securities, which may provide an operational runway potentially into profitability despite a projected full-year 2026 net loss of $1.50 per share. Near-term catalysts in January 2027 and 1H27, including lung cancer, glioblastoma, and Phase 3 trial initiations, could further validate the pipeline and expand the addressable opportunity.

Bears say

Tango Therapeutics is exposed to substantial fundamental risk because its outlook depends on unproven clinical assets, including TNG-908 and the USP1i program, that may fail to demonstrate efficacy or may encounter safety issues severe enough to halt development. As a biotechnology company with a narrow pipeline concentrated in precision oncology, it faces meaningful regulatory and commercialization uncertainty, especially if current or future therapies compete more effectively against its candidates. The negative stance is reinforced by the possibility that the company cannot achieve sales estimates, leaving it reliant on programs that remain vulnerable to clinical, regulatory, and market setbacks.

Tango Therapeutics (TNGX) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 40% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tango Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Tango Therapeutics (TNGX) Analyst Forecast & Price Prediction

Get the latest Tango Therapeutics (TNGX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Tango Therapeutics (TNGX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tango Therapeutics (TNGX) Forecast

Analysts have given Tango Therapeutics (TNGX) a Buy based on their latest research and market trends.

According to 10 analysts, Tango Therapeutics (TNGX) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tango Therapeutics (TNGX)


Tango Therapeutics (TNGX) Analyst Forecast & Price Prediction

Get the latest Tango Therapeutics (TNGX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Tango Therapeutics (TNGX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover TNGX stock data and trends